-
ARMAN LIE
Partner·Hong Kong
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MR. LIE IS A PARTNER IN THE CAPITAL MARKET GROUP AT FANGDA’S HONG KONG OFFICE. HE SPECIALIZES IN CAPITAL MARKETS, M&A, PUBLIC AND PRIVATE PLACEMENTS AND OTHER FINANCING TRANSACTIONS, AND REPRESENTS LEADING CORPORATE AND FINANCIAL INSTITUTIONS, PRIVATE EQUITY FUNDS AND LISTED COMPANIES.
Education
The University of Hong Kong, PCLL
The University of Hong Kong, LL.B.
Professional Qualification
Admitted to practice in Hong Kong SAR
Work Language
English
Mandarin Chinese
Cantonese
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Represented Jinxin Fertility Group Limited (HKEx stock code: 1951) in its over US $400 million global offering and initial public offering on the Main Board of the HKEx
- Represented Morgan Stanley and Huatai Financial as placing agents in the proposed H-Share private placement of WuXi AppTec Co., Ltd. (HKEx stock code: 2359) worth over HK $7 billion
- Represented WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) and its controlling shareholders in successive primary and secondary placing transactions since WuXi’s listing on the Main Board of the HKEx, with an aggregate transaction value of over US $5 billion
- Represented Morgan Stanley, Huatai Financial and Goldman Sachs, as sponsors and global coordinators, in the US $1 billion global H-Share offering of WuXi AppTec Co., Ltd. (HKEx stock code: 2359) on the Main Board of the HKEx
- Represented Bank of America, Morgan Stanley and China Merchants Securities as sponsors in the US $510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) on the Main Board of the HKEx
- Represented Citigroup and CCB International as joint sponsors and joint global coordinators in connection with the US $113 million global offering and initial public offering of Zhaoqing Kepei Education Group Limited (HKEx stock code: 1890) on the Main Board of the HKEx
- Represented Jinxin Healthcare Investment Management Group, a Sichuan-based international healthcare group, in its series A round of equity financing of USD $140 million from Capital Group and GL Capital as pre-IPO investors
- Advised Fujifilm Corporation, as cornerstone investor, in the initial public offering and listing of China Resources Pharmaceutical Group Limited (HKEx stock code: 3320) on the Main Board of the HKEx
- Advised a PRC-based real estate property developer in a syndicated loan of USD $175 million led by China CITIC Bank for group restructuring and settlement of outstanding exchangeable bonds
- Advised Harrow International and its affiliates in a term loan facility of HKD $600 million from the Bank of East Asia and Heng Sang Bank for construction of the Harrow schools in Hong Kong
